Enthera

Preclinical data demonstrate crucial role of Transmembrane Protein 219 (TMEM219) in exacerbating inflammatory bowel disease (IBD) by inducing intestinal epithelial stem cell (ISC) death and impairing mucosal healing Findings support Phase 1 clinical devel

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing first-in-class antibody therapeutics targeting the Insulin Growth Factor Binding Protein (IGFBP) family for selected inflammatory diseases, confirms its attendance at the Eur

Industry veteran Dr. Olson moves from Enthera's Board to take the helm as CEO Ent001 Phase 1a trial in healthy volunteers completed with positive topline safety results Company has initiated enrollment for Ent001 Phase 1b trial in patients with moderately

Phase 1 study in healthy volunteers lays groundwork for Ent001 evaluation in patients with inflammatory bowel disease and type 1 diabetes Milan, Italy, March 7, 2023 - Enthera Pharmaceuticals ("Enthera"), a biotech company developing first-in-class biolog

Milan, Italy, February 16, 2023 - Enthera Pharmaceuticals ("Enthera"), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the appointment of Filippo Canducci MD, PhD as Chief Medical Officer. Dr. Cand

Milano, 4 maggio 2022 - Enthera Pharmaceuticals ("Enthera"), azienda biotecnologica che sviluppa farmaci biologici "first in class" per alcune malattie autoimmuni nelle quali è coinvolto un nuovo meccanismo di apoptosi, annuncia oggi la nomina di Aled Wil

Milan, Italy, 4 May 2022 - Enthera Pharmaceuticals ("Enthera"), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today announces the appointment of Aled Williams

New publication titled 'The IGFBP3/TMEM219 pathway regulates β-cell homeostasis' published in leading peer-review journal, Nature Communications The research confirms that the recently discovered 'IGFBP3/TMEM219' apoptosis pathway plays a key role in beta

Antonio Speziale joins Enthera with drug development and commercialization experience from roles at Galapagos, Shire, Novartis, Genzyme and Wyeth Milan, Italy, 4 October 2021 - Enthera Pharmaceuticals ("Enthera"), a biotech company developing first-in-cla

The OpenZone drug discovery unit will be used to support Enthera's new discovery program and accelerate its mission to identify new treatments for intractable autoimmune diseases Milan, Italy, 7 July 2021 - Enthera Pharmaceuticals ("Enthera"), a biotech c